Moteur de recherche d’entreprises européennes
Financement de l’UE (12,1 M €) : MISE EN ŒUVRE, DÉPLOIEMENT ET VALIDATION DANS LE MONDE RÉEL D’OUTILS DE DÉTECTION PRÉCOCE ET D’AMÉLIORATION DU MODE DE VIE Hor17/11/2023 Programme de recherche et d'innovation de l'UE « Horizon »
Vue d’ensemble
Texte
MISE EN ŒUVRE, DÉPLOIEMENT ET VALIDATION DANS LE MONDE RÉEL D’OUTILS DE DÉTECTION PRÉCOCE ET D’AMÉLIORATION DU MODE DE VIE
Alzheimer's disease (AD), the main cause of dementia, is one of the major global health challenges of our time. This disabling disorder affects 55 million people worldwide, with costs above $1.3 trillion. With 67 million people at risk for AD dementia (prodromal and preclinical AD) in Europe alone, it is a major unmet public health need, with increasing burden for European economies, healthcare and social care systems and a concern for the future. Yet, prevention and early detection strategies have been lacking. Recent advances in disease-modifying therapies and the huge potential benefits of preventive multidomain interventions based on modifiable lifestyle and vascular factors (prevention potential ~ 40%) provide new opportunities. New developments in blood-based biomarkers (BBMs) and digital cognitive tests enable broader, cost-effective testing. The AD-RIDDLE platform is envisioned to revolutionize how AD is detected and diagnosed, prevented and treated across healthcare settings (HCS). AD-RIDDLE centres around a toolbox platform concept, providing a series of validated tools at each key step to enable HCS and practitioners to deploy enhanced AD management across diverse patient populations. The AD-RIDDLE toolbox platform will include a) community outreach tools to increase awareness/activation on AD prevention; b) combination of easily available, clinically validated biomarkers: digital cognitive tools and BBMs, for early detection of AD dementia risk; c) validated algorithms supporting clinical decisions, to identify people who can benefit from specific preventive therapies (pharma and/or non-pharma) using precision prevention approach. The toolbox usability and efficacy with be tested in real-world settings. We expect that the AD-RIDDLE modular and flexible design can facilitate broad uptake from different healthcare systems, and its tools can advance research to develop cost-effective preventive therapies for AD, with scalability for other dementias
| Imperial College of Science Technology and Medicine | ? |
| ALZHEIMER'S DISEASE INTERNATIONAL THE INTERNATIONAL FEDERATION OF ALZHEIMER'S DISEASE AND RELATED DISORDERS SOCIETIES Inc. | 157 000 € |
| Alzheimer Europe | 538 000 € |
| C2N DIAGNOSTICS LLC | 0,00 € |
| Cambridge Cognition Ltd. | 0,00 € |
| COMBINOSTICS Oy | 0,00 € |
| DAVOS ALZHEIMER'S COLLABORATIVE | 0,00 € |
| DAVOS ALZHEIMER'S COLLABORATIVE | 0,00 € |
| Fujirebio Europe N.V. | 0,00 € |
| Fundacio Barcelonabeta Brain Research Center | 1 038 000 € |
| GATES VENTURES LLC | 0,00 € |
| Goeteborgs Universitet | 738 500 € |
| ITA-SUOMEN YLIOPISTO | 929 000 € |
| Karolinska Institutet | 734 250 € |
| Lunds Universitet | 1 095 250 € |
| NEOTIV GmbH | 0,00 € |
| Region Stockholm | 2 932 750 € |
| Sanofi-Aventis Recherche & Developpement | 0,00 € |
| STICHTING AMSTERDAM UMC | 1 121 250 € |
| Stiftelsen Fingers Brain Health Institute | 590 250 € |
| Synapse Research Management Partners SL | 803 250 € |
| Universita Degli Studi Di Perugia | 519 000 € |
| UNIVERSITEIT MAASTRICHT | 537 000 € |
| Vastra Gotalandsregionen | 356 750 € |
https://cordis.europa.eu/project/id/101132933
Cette annonce se réfère à une date antérieure et ne reflète pas nécessairement l’état actuel. L’état actuel est présenté à la page suivante : Imperial College of Science Technology and Medicine, Londres, Royaume Uni.